Zydus Lifesciences gets NOC from Health Canada; share price down marginally

Zydus Lifesciences

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Zydus Lifesciences share price was down marginally on August 8 despite NOC from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg.

At 09:27am, Zydus Lifesciences was quoting at Rs 942.00, down Rs 3.35, or 0.35 percent, on the BSE.

".... has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets 0.5 &1 mg, a first NOC approval in Canada," company said in its release.

Varenicline is used as an aid in smoking cessation, and it is a partial nicotinic acetylcholine receptor agonist, designed to partially activate this system while displacing nicotine at its sites of action in the brain, it added.

ZDS-Varenicline tablets will be produced at Zydus Lifescience Ltd, SEZ, Ahmedabad.

Catch all the market action on our live blog

The meeting of the board of directors of the company will be held on August 12, 2025, to consider, apart from other agenda items, approval of unaudited financial results for the quarter ended on June 30, 2025.

In the month of July, the company completed the acquisition of Amplitude Surgical and holds 85.6% of the share capital and voting rights of Amplitude Surgical.

Also, company received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg.

In the month of June, the company received two observations from US Food and Drug Administration (USFDA) post inspection conducted between June 9-18 at its oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.

The share touched a 52-week high of Rs 1,323.90 and a 52-week low of Rs 797.05 on 09 August, 2024 and 07 April, 2025, respectively.

Currently, the stock is trading 28.85 percent below its 52-week high and 18.19 percent above its 52-week low.

The market capitalisation of the company stands at Rs 94,787.24 crore.

The share price slipped 246 percent in the last one-year.